Alberto-Culver Founder Leonard Lavin Joins Histogen Board of Directors
SAN DIEGO, February 14, 2008
- Histogen, Inc., a regenerative medicine company developing solutions
based on the products of newborn fibroblasts, today announced that
Leonard Lavin, founder and chairman emeritus of the Alberto-Culver
Company, has joined Histogen's Board of Directors.
In addition to his distinguished career with
Alberto-Culver, a Fortune 1000 consumer products company, Leonard
Lavin's experience and interests cross various industries. In 1946,
Lavin joined Halgar, Inc., a company specializing in toiletry products,
where he was instrumental in building the company into one of the
leaders in its field. Lavin also formed the Excello Sales Agency, where
he gained exclusive advertising and sales rights for Stopette spray
deodorant, which went on to become the number one product of its kind.
Leonard Lavin and his wife Bernice bought
Alberto-Culver Company in 1955 for $400,000, and turned it into a
multi-billion dollar company. By positioning his products and making
innovative use of television advertisements, Lavin has supplied the
world with some of the most well known hair, skin and personal care
products.
"Mr. Lavin's extraordinary business acumen will
be invaluable as Histogen enters a tremendous stage of growth in 2008,"
said Gail K. Naughton Ph.D., Histogen founder and Chairman of the Board.
"Leonard has proven himself to be a marketing genius, and having
someone with his expertise join the board truly validates Histogen's
distinctive business model."
Histogen, launched in 2007, seeks to redefine
regenerative medicine by developing a series of high value products
without the use of embryonic stem cells or animal products. The
company's business plan benefits from the lessons learned at Advanced
Tissue Sciences, and focuses on near, mid and long term products that
are either self-pay or reimbursable.
"I am excited to be a new director on Histogen's
board, and look forward to contributing to the company's success" said
Lavin." The field of regenerative medicine offers many potential
therapeutic and cosmetic benefits, and Histogen's unique technology
positions the company to be a global leader in the field."
Through Histogen's proprietary bioreactors that
mimic the embryonic environment, newborn fibroblasts are encouraged to
naturally produce the vital proteins and growth factors from which the
company has developed its rich product portfolio.
0 comment :
Thanks for your comments.